Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
| Autor: | Filip, Baert, Elien, Glorieus, Cathérine, Reenaers, Geert, D'Haens, Harald, Peeters, Dennis, Franchimont, Olivier, Dewit, Philippe, Caenepeel, Edouard, Louis, Gert, Van Assche, L, Terriere |
|---|---|
| Přispěvatelé: | AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Anti-Inflammatory Agents Antibodies Monoclonal Humanized Maintenance Chemotherapy Young Adult Crohn Disease Internal medicine Azathioprine Adalimumab medicine Humans Treatment Failure Child Aged Retrospective Studies Crohn's disease business.industry Remission Induction Gastroenterology Antibodies Monoclonal Retrospective cohort study General Medicine Middle Aged medicine.disease Infliximab Surgery C-Reactive Protein Concomitant Child Preschool Cohort Multivariate Analysis Female business De-escalation Immunosuppressive Agents medicine.drug Cohort study |
| Zdroj: | Journal of Crohn s & colitis, 7(2), 154-160. Elsevier |
| ISSN: | 1876-4479 1873-9946 |
| Popis: | BACKGROUND AND AIMS: Adalimumab is efficacious in inducing and maintaining remission in Crohn's disease but dose escalation is needed in 30-40% after 1 year. Attempts for dose de-escalation have not been studied. This study aimed to assess the need for, predictors, and outcome of dose escalation and de-escalation in a large cohort of adalimumab treated Crohn's patients. METHODS: All consecutive patients treated with open label adalimumab for active Crohn's disease from the participating centres were included in this cohort study. A detailed retrospective chart review was performed to look for possible factors predicting outcome. RESULTS: Eighty four percent of 720 patients had a primary response and were followed up for a median of 14 months. Thirty four percent needed escalation after a median of 7 months (0-55 months). Multivariate predictors for dose escalation were the following: prior anti-TNF use (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|